Disclaimer

Cipla was founded in 1935 and has played a key role in pioneering India’s pharmaceutical industry and making it self-reliant. It has 50 manufacturing plants that exceed world standards and produce over 1,200 products that cater to just about every illness. Over 75 years its continuous innovation in R & D has resulted in many firsts in the world. The Company has shown a constant commitment to serve humanity and to support, improve and save millions of lives with its innovative drugs and devices.



As a leader in respiratory medicine, Cipla has the world’s largest range of drugs, dosage forms and devices for asthma and other respiratory illnesses. It has pioneered revolutionary medicines and inhalation therapy in India and given the world many firsts in the management of asthma. For instance its multiple devices have transformed inhalation therapy. And its high quality of medical updates and patient education material help doctors and patients.

The Company set up the Chest Research Foundation (CRF) at Pune, India to conduct research and education on respiratory diseases with emphasis on airway diseases. The CRF is now an autonomous body which continues independent research in various fields of respiratory medicine.

On the completion of its 75th year, Cipla reaffirms its dedication to improve and save lives across the world. Breathefree is a public service initiative funded by an educational grant by Cipla.

For more information log on to www.cipla.com